LGALS9 and cutaneous melanoma: As in cutaneous melanoma, the anti-MAA clonotypes formed frequent inhibitory interactions with tumor cells via PVR – TIGIT/CD96 and with immune cells via Galectin 9 – TIM3 (Fig. 2j and Supplementary Data 4).